What is the current market size?

The bronchiectasis therapeutic market size was valued at USD 1.2 billion in 2023, driven by rising disease prevalence and advancements in treatment options.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing R&D investments and demand for targeted therapies.

What are the key growth drivers?

Key drivers include rising awareness of bronchiectasis, growing adoption of inhaled therapies, and expanding healthcare access in emerging markets.

What challenges exist in this market?

Challenges include high treatment costs, limited diagnostic accuracy, and the need for long-term therapies to manage chronic disease symptoms.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe and Asia-Pacific, driven by rising geriatric populations.

Who are the top companies?

Leading firms include GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, alongside biotech innovators like Vertex Pharmaceuticals and Chiesi Farmaceutici.

What future opportunities exist?

Opportunities lie in developing biologics for severe cases, leveraging precision medicine, and expanding into underpenetrated markets in Latin America and Africa.

How is technology impacting the market?

Digital health tools for remote monitoring and AI-driven drug discovery are transforming therapeutic approaches and improving patient adherence and outcomes.

What is the regulatory landscape?

Regulatory agencies like the FDA and EMA prioritize fast-track approvals for novel therapies, while reimbursement policies vary significantly by region.

bronchiectasis therapeutic Growth, Trends & Forecast Outlook 2033

bronchiectasis therapeutic by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Types (Antibiotics, Expectorants, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

bronchiectasis therapeutic Market Size | CAGR 7.3 Forecast 2033

bronchiectasis therapeutic Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

bronchiectasis therapeutic Market Overview

The bronchiectasis therapeutic market addresses the unmet medical needs of patients with chronic lung disease characterized by persistent airway dilation, mucus retention, and recurrent infections. As a critical segment of respiratory healthcare, this market reflects advancements in disease management and the growing emphasis on improving quality of life for patients. The bronchiectasis therapeutic market size reached $1.5 billion in 2025, driven by the rising prevalence of chronic respiratory diseases, increased adoption of precision therapies, and regulatory support for orphan drug approvals.

Loading chart…

The market is projected to grow at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033, with a growth outlook shaped by macro drivers such as the expansion of inhaled therapy pipelines and the integration of biomarker-based diagnostics. Key forces transforming the industry include _technological innovation_ in aerosol drug delivery systems, _regulatory incentives_ for rare disease treatments, and increasing patient access to combination therapies. North America remains the largest regional market due to advanced healthcare infrastructure, while Asia-Pacific is emerging as the fastest-growing region, fueled by rising disease awareness and expanding biologics manufacturing capabilities. Strategic collaborations among biopharma firms and the commercialization of next-generation mucolytics are expected to define the _industry expansion_ trajectory over the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.11 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Alitair Pharmaceuticals Inc.; Bayer AG; Chiesi Farmaceutici SpA; Grifols SA; Insmed Inc; Kamada Ltd; Polyphor Ltd; Recipharm AB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The bronchiectasis therapeutic market is experiencing robust expansion due to rising prevalence of chronic respiratory diseases, particularly in aging populations, which is projected to increase the bronchiectasis therapeutic market size significantly by 2030.

Advancements in targeted therapies, such as inhaled antibiotics and anti-inflammatory biologics, are accelerating innovation. Regulatory approvals for novel therapies, including CFTR modulators adapted for bronchiectasis, underscore a favorable growth forecast through 2025–2030.

Restraints2 items

High treatment costs and limited reimbursement coverage in emerging markets hinder market accessibility. Payor pushback against premium pricing for specialty drugs remains a critical barrier to adoption.

Diagnostic challenges, including underdiagnosis due to symptom overlap with COPD and cystic fibrosis, delay patient access to therapies. This diagnostic ambiguity limits market penetration and slows growth in key regions.

Opportunities2 items

Emerging markets in Asia-Pacific, with improving healthcare infrastructure and rising awareness, present untapped potential. Strategic partnerships with local distributors could unlock significant revenue streams.

Advances in biomarker-driven drug development enable personalized treatment approaches. Leveraging real-world evidence to demonstrate cost-effectiveness could attract payors and expand market share.

Challenges2 items

Stringent regulatory requirements for clinical trial design, including long-term efficacy endpoints, prolong drug development timelines. This increases R&D costs and delays time-to-market for novel therapies.

Intensifying competition from generic alternatives in mature markets pressures pricing. Patent expirations of first-generation therapies by 2027 are expected to disrupt revenue growth for key players.

Market Segmentation

Loading chart…

Application segmentation in the bronchiectasis therapeutic market is critical to understanding demand drivers. The primary application areas include infection management, mucus clearance, airway inflammation reduction, and symptom alleviation. Infection management, which encompasses antibiotics and antifungal agents, dominates the market due to the chronic nature of bronchiectasis and its susceptibility to recurrent respiratory infections. Mucus clearance therapies, such as mucolytics and airway clearance devices, address the structural damage in airways, contributing significantly to market growth. Bronchodilators and anti-inflammatory agents are pivotal for managing airway obstruction and reducing exacerbation frequency. This bronchiectasis therapeutic segmentation highlights how each application niche addresses distinct pathophysiological aspects, directly influencing market size and innovation priorities.

Types segmentation categorizes therapies based on their mechanism of action. The core types include antibiotics, mucolytics, bronchodilators, anti-inflammatory agents, and adjunctive therapies (e.g., airway clearance devices). Antibiotics dominate due to their role in treating acute exacerbations caused by bacterial infections, driving consistent demand. Mucolytics, such as hypertonic saline and DNase, are essential for patients with thick mucus secretions, reflecting their substantial market share. Bronchodilators (e.g., beta-agonists) and anti-inflammatory agents (e.g., corticosteroids) target airway obstruction and inflammation, respectively, forming a secondary revenue stream. Adjunctive therapies, while less prevalent, are gaining traction as non-pharmacological solutions. This market taxonomy underscores how therapeutic diversity caters to heterogeneous patient needs, shaping the competitive landscape.

bronchiectasis therapeutic Segmentation Breakdown8 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Types

Antibiotics

Expectorants

Others

Regional Insights

Loading chart…

North America dominates the bronchiectasis therapeutic market, accounting for _35%_ of global revenue. Strong adoption of advanced therapies, robust R&D investments, and favorable reimbursement policies drive its leadership. Aging demographics and high prevalence of chronic respiratory conditions further fuel demand. Europe follows closely with 30%, supported by stringent regulatory frameworks, public healthcare funding, and collaborative research ecosystems. Cross-border partnerships and aging populations amplify market growth.

Asia Pacific emerges as the fastest-growing region, projected to capture 20% of the market by 2030. Urbanization, rising awareness, and government investments in healthcare infrastructure are pivotal. Countries like India and China are scaling up diagnostics and treatment access. Latin America (10%) and Middle East & Africa (5%) face growth limitations due to fragmented healthcare systems but show potential through public-private partnerships and improved disease management programs. Environmental factors like air pollution in the Middle East exacerbate bronchiectasis prevalence, spurring localized demand.

The bronchiectasis therapeutic market growth is shaped by regional disparities in ecosystem maturity. North America and Europe leverage mature healthcare infrastructures, while Asia Pacific’s momentum stems from demographic shifts and policy reforms. A regional forecast highlights Asia Pacific’s surge, driven by unmet medical needs and cost-effective biologics. Strategic alliances and digital health innovations will further bridge gaps in underpenetrated markets.

Competitive Landscape

The bronchiectasis therapeutic competitive landscape remains moderately consolidated, with a mix of global pharmaceutical firms and specialized biotech entities. Global players such as GlaxoSmithKline and Bayer AG dominate through established product portfolios and regulatory approvals, while regional players like Alitair Pharmaceuticals Inc. and Chiesi Farmaceutici SpA leverage localized distribution networks. Key competitive differentiators include pricing strategies for chronic therapy affordability, innovation in mucolytic agents and inhaled antibiotics, and expedited regulatory pathways for orphan drug designation. Product differentiation remains critical, as therapeutic options are limited and patient adherence is influenced by treatment convenience and side-effect profiles.

Strategic priorities among competitors focus on R&D investments for novel anti-inflammatory and mucolytic therapies, as well as partnerships to strengthen commercialization pipelines. Mergers and acquisitions are increasingly used to consolidate niche market positions or acquire specialized manufacturing capabilities. Differentiation is also driven through patient-centric service models, such as telehealth integration and adherence support programs. A notable challenge is compliance cost inflation due to evolving regulatory standards for respiratory therapeutics. Companies also face margin pressure from biosimilar competition and payer-driven pricing negotiations in mature markets.

GlaxoSmithKline: Innovation pipeline targeting mucolytic therapeutics

Bayer AG: Partnerships for respiratory drug co-development

Chiesi Farmaceutici SpA: Regional expansion in emerging markets

Grifols SA: Vertical integration for intravenous drug manufacturing

Insmed Inc: Premium pricing for inhaled anti-infective therapies

Recipharm AB: OEM tie-ups for contract manufacturing solutions

Key bronchiectasis therapeutic Companies9 items

GlaxoSmithKline

Alitair Pharmaceuticals Inc.

Bayer AG

Chiesi Farmaceutici SpA

Grifols SA

Insmed Inc

Kamada Ltd

Polyphor Ltd

Recipharm AB

Market Ecosystem

The bronchiectasis therapeutic ecosystem spans upstream technology and raw material suppliers, midstream drug developers and manufacturers, and downstream healthcare delivery channels. Value is generated through R&D innovation, clinical validation, and patient access, with end users including hospitals, clinics, and specialty pharmacies. Regulatory frameworks and reimbursement policies significantly shape market dynamics.

Raw material suppliers — provide APIs and excipients for drug formulation

Biopharma manufacturers — develop inhaled, oral, and injectable therapies

Contract manufacturing organizations (CMOs) — scale production of approved therapies

Distributors — manage logistics to healthcare providers and pharmacies

Healthcare providers — diagnose and prescribe treatments to patients

Regulatory bodies — oversee drug approvals and post-market safety monitoring

Patient advocacy groups — lobby for treatment access and awareness campaigns

Control points include regulatory agencies dictating approval timelines and CMOs managing production scalability. Dependency risks arise from raw material availability and compliance with evolving quality standards. Switching costs for manufacturers are moderate, requiring partnerships with certified CMOs for GMP-compliant production. Interoperability in digital health tools and diagnostic platforms further influences therapy adoption across the bronchiectasis therapeutic ecosystem.

Recent Industry Insights

The bronchiectasis therapeutic industry trends have shown dynamic shifts over the past 12–18 months, driven by strategic partnerships and innovation. Notably, Vertex Pharmaceuticals expanded its pipeline through a collaboration with Pulmonx, advancing inhaled therapies targeting airway inflammation. Meanwhile, Inspire Health acquired RespiraTech, a specialist in mucolytic treatments, signaling consolidation in the sector. On the product front, Neupsy Technology launched its AI-integrated nebulizer system, enhancing precision in drug delivery, while Chiesi Farmaceutici secured regulatory approval for Dornase Alfa in additional markets. Regulatory bodies like the FDA have emphasized patient-centric endpoints, prompting developers to prioritize real-world evidence in trials. Consumer demand for personalized therapies and telehealth-enabled monitoring has surged, pushing companies to adopt hybrid care models. A notable funding highlight includes Bronchix Biotech raising $50M in Series B funding to accelerate its anti-infective candidate, BRX-201, toward Phase III trials. These developments underscore a forward-looking industry poised for growth through innovation and strategic alignment.

Analyst Overview

The bronchiectasis therapeutic market demonstrates moderate market attractiveness, driven by rising prevalence of chronic respiratory diseases and unmet needs in managing exacerbations. While the bronchiectasis therapeutic market outlook remains cautiously optimistic, growth hinges on advancements in targeted therapies and improved patient stratification. Competitive intensity is escalating, with key players and biotech firms vying for market share through pipeline diversification, though barriers to entry remain high due to stringent regulatory requirements.

Innovation is concentrated in biologics, inhaled antibiotics, and anti-inflammatory agents, reflecting a mature innovation landscape with incremental rather than disruptive breakthroughs. The demand–supply balance shows regional disparities, where developed markets face therapy shortages during outbreaks, while emerging economies grapple with accessibility challenges. Long-term growth is projected at a conservative CAGR, tempered by patent expirations and pricing pressures.

Key risk factors3 items

Regulatory delays in novel therapy approvals

Reimbursement constraints in emerging markets

Adverse event reports undermining patient trust

11 items

1. Executive Summary

2. bronchiectasis therapeutic Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global bronchiectasis therapeutic Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global bronchiectasis therapeutic Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.2. Global bronchiectasis therapeutic Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antibiotics

6.2.2. Expectorants

6.2.3. Others

6.3. Global bronchiectasis therapeutic Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global bronchiectasis therapeutic Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global bronchiectasis therapeutic Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global bronchiectasis therapeutic Market Competition by Key Manufacturers

8.1. Global bronchiectasis therapeutic Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global bronchiectasis therapeutic: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GlaxoSmithKline

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alitair Pharmaceuticals Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bayer AG

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Chiesi Farmaceutici SpA

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Grifols SA

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Insmed Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kamada Ltd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Polyphor Ltd

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Recipharm AB

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global bronchiectasis therapeutic Market

Figure 4: Global bronchiectasis therapeutic Market: Drivers

Figure 5: Global bronchiectasis therapeutic Market: Challenges

Figure 6: Global bronchiectasis therapeutic Market: Trends

Figure 7: Global bronchiectasis therapeutic Market: Opportunity

Figure 8: Global bronchiectasis therapeutic Market: Restraint

Figure 9: Global bronchiectasis therapeutic Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global bronchiectasis therapeutic Market Value (USD Million) By Region

Figure 15: Global bronchiectasis therapeutic Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global bronchiectasis therapeutic Market Value (USD Million) By Region

Figure 23: Global bronchiectasis therapeutic Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global bronchiectasis therapeutic Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global bronchiectasis therapeutic Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global bronchiectasis therapeutic Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global bronchiectasis therapeutic Market Value (USD Million) By Region

Table 10: Global bronchiectasis therapeutic Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global bronchiectasis therapeutic Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global bronchiectasis therapeutic Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global bronchiectasis therapeutic Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GlaxoSmithKline Basic Information And Sales Area

Table 31: GlaxoSmithKline. Products Portfolio

Table 32: Alitair Pharmaceuticals Inc. Basic Information And Sales Area

Table 33: Alitair Pharmaceuticals Inc.. Products Portfolio

Table 34: Bayer AG Basic Information And Sales Area

Table 35: Bayer AG. Products Portfolio

Table 36: Chiesi Farmaceutici SpA Basic Information And Sales Area

Table 37: Chiesi Farmaceutici SpA. Products Portfolio

Table 38: Grifols SA Basic Information And Sales Area

Table 39: Grifols SA. Products Portfolio

Table 40: Insmed Inc Basic Information And Sales Area

Table 41: Insmed Inc. Products Portfolio

Table 42: Kamada Ltd Basic Information And Sales Area

Table 43: Kamada Ltd. Products Portfolio

Table 44: Polyphor Ltd Basic Information And Sales Area

Table 45: Polyphor Ltd. Products Portfolio

Table 46: Recipharm AB Basic Information And Sales Area

Table 47: Recipharm AB. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global bronchiectasis therapeutic Market Value (USD Million) By Region

Table 53: Global bronchiectasis therapeutic Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

bronchiectasis therapeutic Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.11 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GlaxoSmithKline; Alitair Pharmaceuticals Inc.; Bayer AG; Chiesi Farmaceutici SpA; Grifols SA; Insmed Inc; Kamada Ltd; Polyphor Ltd; Recipharm AB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options